Long-Term Efficacy and Safety of Iptacopan in Patients with IgA Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1252; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall; P2, P3 | "Long-term ipta treatment led to improvements vs pbo in eGFR trajectory and proteinuria that were also observed after switching from pbo upon REP entry. The new evidence on long-term exposure of ipta supports the established safety profile of complement inhibition with ipta."
Clinical • Late-breaking abstract • Glomerulonephritis • IgA Nephropathy • Pancreatitis • Renal Disease • CFB
|
|
Brad Rovin1; Severina Jacinto-Sanders9; Annabel Rose Magirr9; Ronny Renfurm9; Thomas Hach9; Dana V. Rizk11; Hernan Trimarchi2; Bart D. Maes3; Vlado Perkovic4; Naoki Kashihara5; Hong Zhang6; Jonathan Barratt7,8; Katarina Petrovic-Bulatovic9; Zenab Attari10
|